Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15996418 | 0.95 | MAOB (0.51) | MAOBACHE | |
| SCHEMBL31439940 | 0.91 | MAOB (0.52) | MAOBACHE | |
| SCHEMBL2399096 | 0.91 | MAOB (0.52) | MAOBACHE | |
| SCHEMBL30304462 | 0.90 | ACHE (0.53) | MAOBACHE | |
| SCHEMBL21227666 | 0.90 | ACHE (0.53) | MAOBACHE | |
| SCHEMBL22291527 | 0.90 | ACHE (0.53) | MAOBACHE | |
| SCHEMBL31655718 | 0.90 | ACHE (0.53) | MAOBACHE | |
| SCHEMBL14554544 | 0.87 | MAOB (0.49) | MAOB | |
| SCHEMBL21997754 | 0.85 | SMN1; SMN2 (0.42) | MAOB | |
| SCHEMBL19925980 | 0.84 | MAOB (0.49) | MAOBACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119584961-A | Methods and compounds for modulating huntington's disease | 设计治疗公司 | 2025-03-07 | — | — | CN | disclosed |
| EP-4504339-A2 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. | 2024-10-31 | — | — | US | disclosed |
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240058460-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. | 2024-02-22 | — | — | US | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| US-20240042046-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | DESIGN THERAPEUTICS INC (US) | 2024-02-08 | — | — | US | disclosed |
| WO-2023192642-A2 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | Design Therapeutics, Inc. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| CN-115768765-A | Methods and compounds for treating genetic diseases | 设计治疗公司 | 2023-03-07 | — | — | CN | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | MAOB 1592/4885ACHE 4656/4885 |
| US-20240058460-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | HTT, TARDBP, HYPK | MAOB 1558/4885ACHE 1858/4885 |
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | POLI, POLR2A, POLR2B | MAOB 2295/4885ACHE 4873/4885 |
| US-20240042046-A1 | METHODS AND COMPOUNDS FOR MODULATING HUNTINGTON'S DISEASE | HTT, TARDBP, HYPK | MAOB 1558/4885ACHE 1858/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | MAOB 797/4885ACHE 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.